Insomnia, Narcolepsy, Sleep Disorders

Insomnia, Narcolepsy, Sleep Disorders

Preclinical In Vivo CRO Services for Insomnia, Narcolepsy, and Sleep Disorder Therapeutics

At Anilocus, we are a preclinical Contract Research Organization (CRO) based in San Diego, specializing in in vivo research services for pharmaceutical companies developing products to treat sleep disorders such as insomnia, narcolepsy, and other sleep disruptions.

Our team understands the importance of thorough preclinical testing to ensure the safety and efficacy of novel treatments for sleep disorders. Using our translational animal models of sleep disorders, we utilize state-of-the-art approaches to accurately assess sleep patterns and abnormalities, contributing to the development of innovative therapies. With our multidisciplinary approach and expertise in sleep medicine, we aim to support our Sponsors in their mission to improve the lives of individuals suffering from sleep disturbances. Our commitment to excellence and rigorous laboratory practices make us a preferred CRO partner in the field of sleep disorders.

Contact us! Learn more about our in vivo CRO services:

    We offer quality in vivo services that prioritize your research efforts from start to finish. 

    We utilize animal models of sleep disorders to test drugs and medical devices developed to treat sleep disorders. Commonly studied animal models include mice, rats, flies, and fish. These animal models provide your team with powerful tools to investigate the safety and efficacy of drug products and medical devices.

    Team Anilocus - Preclinical contract research organization (CRO) based in San Diego, California | In vivo research services

    Our In Vivo CRO Benefits

    What We Offer Sponsors:

    Frequently asked questions about our in vivo services for sleep disorder therapeutics:

    • In mice, genetic mutations have been used to study how different genes affect sleep-wake cycles.
    • Rats have been used to study the impacts of specific drugs and environmental conditions on sleep.
    • Flies have been used to study how different hormones and proteins regulate sleep-wake cycles.
    • Fish have been used to study how light exposure and other external factors affect sleep.

    Sleep disruption occurs when the body’s natural sleep-wake cycle is thrown off balance. The neurobiology of sleep disruption begins with the suprachiasmatic nucleus (SCN), a region of the brain that is responsible for controlling the circadian rhythm. The circadian rhythm is a 24-hour cycle that affects various bodily functions, including sleep. When the SCN is disrupted, it can throw off the body’s natural sleep-wake cycle, leading to sleep disruption.

    Drug molecules can target receptors in the brain that control the sleep-wake cycle. These drugs can be used to induce and maintain sleep, as well as reduce insomnia. Biologics are drugs derived from living organisms or their products, such as bacteria or viruses, that are used to treat sleep disorders. These often target proteins or hormones related to the sleep-wake cycle. Finally, gene-based therapies involve manipulating a patient’s genetic code to treat sleep disorders. This could involve delivering the gene for a specific receptor into the brain to reduce insomnia.

    • Sedative-hypnotics, such as benzodiazepines (Xanax, Valium, Klonopin, Lunesta)
    • Non-benzodiazepine hypnotics (Ambien, Sonata, Rozerem)
    • Melatonin receptor agonists (Ramelteon)
    • Orexin receptor antagonists (Belsomra)
    • Anti-depressants
    • Antihistamines
    • Beta-blockers

    In the United States, there are at least 108 clinical trials for the treatment of insomnia that are currently recruiting participants. The current clinical trials provide intervention either through drug therapy alone or in combination with behavioral or physical therapy.

    At least three are in Early Phase 1 or Phase 1 while the others have progressed past Phase 2. The drugs being tested include orexin antagonists BELSOMRA® (suvorexant), QUVIVIQ® (daridorexant), and Seltorexant (JNJ-42847922) or sedative-hypnotics like Zolpidem.

    Check out the following articles about pharmacology of pharmaceuticals developed for the treatment of sleep disorders:

    1. Campbell R, Chabot I, Rousseau B, Bridge D, Nicol G, Meier G. Understanding the unmet needs in insomnia treatment: a systematic literature review of real-world evidence. Int J Neurosci. 2023;133(8):864-878. doi:10.1080/00207454.2021.1995383.
    2. Najib J, Toderika Y, Dima L. Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia. Am J Ther. 2023;30(4):e360-e368. doi:10.1097/MJT.0000000000001647.
    3. Ziemichód W, Kurowska A, Grabowska K, Kurowska M, Biała G. Characteristics of Seltorexant-Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety. Molecules. 2023;28(8):3575. Published 2023 Apr 19. doi:10.3390/molecules28083575.
    4. Fagan H, Jones E, Baldwin DS. Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies. CNS Drugs. 2023;37(1):1-12. doi:10.1007/s40263-022-00974-6.
    5. Mignot E, Bogan RK, Emsellem H, et al. Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia [published online ahead of print, 2023 Mar 8]. Sleep. 2023;zsad049. doi:10.1093/sleep/zsad049.